NZ601376A - Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors - Google Patents
Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitorsInfo
- Publication number
- NZ601376A NZ601376A NZ601376A NZ60137610A NZ601376A NZ 601376 A NZ601376 A NZ 601376A NZ 601376 A NZ601376 A NZ 601376A NZ 60137610 A NZ60137610 A NZ 60137610A NZ 601376 A NZ601376 A NZ 601376A
- Authority
- NZ
- New Zealand
- Prior art keywords
- indazol
- pyridine
- imidazo
- substituted
- carboxamide compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- AYAOSDNSSUARDZ-UHFFFAOYSA-N n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide Chemical class C1=CC=CN2C(C(NC=3C=4C=NNC=4C=CC=3)=O)=CN=C21 AYAOSDNSSUARDZ-UHFFFAOYSA-N 0.000 title 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000005152 nicotinamide Nutrition 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28872909P | 2009-12-21 | 2009-12-21 | |
| PCT/US2010/061341 WO2011079076A1 (en) | 2009-12-21 | 2010-12-20 | Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ601376A true NZ601376A (en) | 2014-03-28 |
Family
ID=43568700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ601376A NZ601376A (en) | 2009-12-21 | 2010-12-20 | Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8841455B2 (enExample) |
| EP (1) | EP2516433B1 (enExample) |
| JP (2) | JP5739448B2 (enExample) |
| KR (1) | KR101779630B1 (enExample) |
| CN (1) | CN102822170B (enExample) |
| AR (1) | AR079541A1 (enExample) |
| AU (1) | AU2010333752B2 (enExample) |
| BR (1) | BR112012017123B1 (enExample) |
| CA (1) | CA2785338C (enExample) |
| CL (1) | CL2012001699A1 (enExample) |
| CO (1) | CO6561821A2 (enExample) |
| CR (1) | CR20120389A (enExample) |
| DK (1) | DK2516433T3 (enExample) |
| ES (1) | ES2494590T3 (enExample) |
| HR (1) | HRP20140770T1 (enExample) |
| IL (1) | IL220544A (enExample) |
| ME (1) | ME01894B (enExample) |
| MX (1) | MX2012007329A (enExample) |
| MY (1) | MY163791A (enExample) |
| NZ (1) | NZ601376A (enExample) |
| PL (1) | PL2516433T3 (enExample) |
| PT (1) | PT2516433E (enExample) |
| RS (1) | RS53500B1 (enExample) |
| RU (1) | RU2562977C2 (enExample) |
| SG (1) | SG181861A1 (enExample) |
| SI (1) | SI2516433T1 (enExample) |
| SM (1) | SMT201400142B (enExample) |
| TW (1) | TWI471326B (enExample) |
| UA (1) | UA108222C2 (enExample) |
| WO (1) | WO2011079076A1 (enExample) |
| ZA (1) | ZA201205505B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2835553T3 (es) | 2009-08-10 | 2021-06-22 | Biosplice Therapeutics Inc | Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos |
| CN102821607B (zh) | 2009-12-21 | 2014-12-17 | 萨穆梅德有限公司 | 1H-吡唑并[3，4-b]吡啶及其治疗应用 |
| KR101779630B1 (ko) * | 2009-12-21 | 2017-09-18 | 어레이 바이오파마 인크. | ｃＦＭＳ 억제제로서 치환된 Ｎ-（１Ｈ-인다졸-４-일）이미다조［１,２-ａ］피리딘-３-카복사미드 화합물 |
| UY33801A (es) | 2010-12-13 | 2013-06-28 | Array Biopharma Inc | COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III |
| HRP20190281T1 (hr) | 2011-09-14 | 2019-05-31 | Samumed, Llc | Indazol-3-karboksamidi i njihova uporaba kao inhibitora signalizacijskog puta wnt/b-katenin |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| WO2013166319A1 (en) * | 2012-05-02 | 2013-11-07 | Kansas State University Research Foundation | Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3c or 3c-like proteases of picornaviruses, caliciviruses and coronaviruses |
| PL2770994T3 (pl) | 2012-05-04 | 2020-03-31 | Samumed, Llc | 1H-Pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne |
| EP2943198B1 (en) | 2013-01-08 | 2019-07-17 | Samumed, LLC | 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof |
| KR101756934B1 (ko) | 2014-07-08 | 2017-07-12 | 연세대학교 산학협력단 | 피롤로[1,2-a]피라진 유도체, 이의 약학적으로 허용가능한 염, 이들 화합물의 제조방법 및 이를 유효성분으로 함유하는 골다공증 치료 또는 예방용 약학조성물 |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| MX2017008218A (es) | 2014-12-22 | 2017-10-18 | Five Prime Therapeutics Inc | Anticuerpos anti-csf1r para tratar pvns. |
| CN204833440U (zh) | 2015-07-29 | 2015-12-02 | 山东新北洋信息技术股份有限公司 | 识读组件及纸币清分机 |
| WO2017024010A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10188634B2 (en) | 2015-08-03 | 2019-01-29 | Samumed, Llc | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10285982B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| WO2017023984A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| WO2017023986A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017023987A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| US10519169B2 (en) | 2015-08-03 | 2019-12-31 | Samumed, Llc | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10231956B2 (en) | 2015-08-03 | 2019-03-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10392383B2 (en) | 2015-08-03 | 2019-08-27 | Samumed, Llc | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
| WO2017023975A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| KR20180080262A (ko) | 2015-11-06 | 2018-07-11 | 사뮤메드, 엘엘씨 | 골관절염의 치료 |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| ES2933109T3 (es) | 2016-06-01 | 2023-02-02 | Biosplice Therapeutics Inc | Proceso para preparar N-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida |
| CN110709082A (zh) | 2016-10-21 | 2020-01-17 | 萨穆梅德有限公司 | 吲唑-3-甲酰胺的使用方法及其作为Wnt/β-连环蛋白信号传导途径抑制剂的用途 |
| WO2018083635A2 (en) | 2016-11-04 | 2018-05-11 | Auckland Uniservices Limited | Tricyclic heterocyclic derivatives and uses thereof |
| KR102558716B1 (ko) | 2016-11-07 | 2023-07-21 | 사뮤메드, 엘엘씨 | 단일-투여량, 즉시-사용가능한 주사용 제제 |
| JP6934261B2 (ja) * | 2017-05-24 | 2021-09-15 | アビスコ セラピューティクス カンパニー リミテッド | Ｎ−（アザアリール）シクロラクタム−１−カルボキサミド誘導体、その製造方法および応用 |
| EP4458810A1 (en) | 2021-12-28 | 2024-11-06 | Nippon Shinyaku Co., Ltd. | Indazole compound and pharmaceutical |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3952101A (en) | 1975-04-14 | 1976-04-20 | Smithkline Corporation | α-Amino methyl-5-hydroxy-2-pyridinemethanols |
| WO2001092257A1 (en) * | 2000-05-26 | 2001-12-06 | Neurogen Corporation | Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands |
| ES2336243T3 (es) | 2005-01-26 | 2010-04-09 | Schering Corporation | Derivados de 3-(indazol-5-il)-(1,2,4)triazina y composiciones similares como inhibidores de proteina quinasa para el tratamiento del cancer. |
| MX2007014377A (es) * | 2005-05-17 | 2008-02-06 | Plexxikon Inc | Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina. |
| PL1902026T3 (pl) | 2005-06-24 | 2010-07-30 | Lilly Co Eli | Pochodne tetrahydrokarbazolu użyteczne jako modulatory receptora androgenowego (SARM) |
| RU2008130111A (ru) | 2005-12-22 | 2010-01-27 | Алькон Рисерч, Лтд. (Us) | (индазол-5-ил)пиразины и (1,3-дигидроиндол-2-он)пиразины для лечения опосредованнызх rно-киназой заболеваний и состояний |
| EP2120938A4 (en) * | 2006-12-20 | 2010-12-08 | Merck Sharp & Dohme | IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES |
| JP5374492B2 (ja) | 2007-04-03 | 2013-12-25 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼ阻害薬としてのイミダゾ［１，２−ａ］ピリジン化合物 |
| WO2009071483A1 (en) | 2007-12-07 | 2009-06-11 | Via Pharmaceuticals, Inc. | 1- (indaz0l-5-yl) -ureas as diacylglycerol acyltransferase inhibitors |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| ES2526966T3 (es) * | 2008-06-05 | 2015-01-19 | Glaxo Group Limited | Compuestos novedosos |
| KR101779630B1 (ko) * | 2009-12-21 | 2017-09-18 | 어레이 바이오파마 인크. | ｃＦＭＳ 억제제로서 치환된 Ｎ-（１Ｈ-인다졸-４-일）이미다조［１,２-ａ］피리딘-３-카복사미드 화합물 |
| UY33801A (es) * | 2010-12-13 | 2013-06-28 | Array Biopharma Inc | COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III |
-
2010
- 2010-12-20 KR KR1020127019199A patent/KR101779630B1/ko not_active Expired - Fee Related
- 2010-12-20 CA CA2785338A patent/CA2785338C/en active Active
- 2010-12-20 MX MX2012007329A patent/MX2012007329A/es active IP Right Grant
- 2010-12-20 ME MEP-2014-99A patent/ME01894B/me unknown
- 2010-12-20 RU RU2012131129/04A patent/RU2562977C2/ru active
- 2010-12-20 HR HRP20140770AT patent/HRP20140770T1/hr unknown
- 2010-12-20 UA UAA201208998A patent/UA108222C2/ru unknown
- 2010-12-20 US US13/517,938 patent/US8841455B2/en active Active
- 2010-12-20 AU AU2010333752A patent/AU2010333752B2/en not_active Ceased
- 2010-12-20 EP EP10798683.8A patent/EP2516433B1/en active Active
- 2010-12-20 AR ARP100104761A patent/AR079541A1/es active IP Right Grant
- 2010-12-20 MY MYPI2012002855A patent/MY163791A/en unknown
- 2010-12-20 PL PL10798683T patent/PL2516433T3/pl unknown
- 2010-12-20 NZ NZ601376A patent/NZ601376A/en not_active IP Right Cessation
- 2010-12-20 WO PCT/US2010/061341 patent/WO2011079076A1/en not_active Ceased
- 2010-12-20 DK DK10798683.8T patent/DK2516433T3/da active
- 2010-12-20 SG SG2012046009A patent/SG181861A1/en unknown
- 2010-12-20 BR BR112012017123-2A patent/BR112012017123B1/pt not_active IP Right Cessation
- 2010-12-20 JP JP2012546120A patent/JP5739448B2/ja not_active Expired - Fee Related
- 2010-12-20 RS RSP20140440 patent/RS53500B1/sr unknown
- 2010-12-20 SI SI201030706T patent/SI2516433T1/sl unknown
- 2010-12-20 ES ES10798683.8T patent/ES2494590T3/es active Active
- 2010-12-20 PT PT107986838T patent/PT2516433E/pt unknown
- 2010-12-20 CN CN201080064462.XA patent/CN102822170B/zh not_active Expired - Fee Related
- 2010-12-21 TW TW99145074A patent/TWI471326B/zh not_active IP Right Cessation
-
2012
- 2012-06-21 IL IL220544A patent/IL220544A/en active IP Right Grant
- 2012-06-21 CL CL2012001699A patent/CL2012001699A1/es unknown
- 2012-07-19 CO CO12122160A patent/CO6561821A2/es unknown
- 2012-07-20 ZA ZA2012/05505A patent/ZA201205505B/en unknown
- 2012-07-20 CR CR20120389A patent/CR20120389A/es unknown
-
2014
- 2014-09-30 SM SM201400142T patent/SMT201400142B/xx unknown
-
2015
- 2015-01-22 JP JP2015010346A patent/JP2015107999A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ601376A (en) | Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors | |
| EA201290305A1 (ru) | Производные трициклического пиразоламина | |
| EA201270498A1 (ru) | 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения заболеваний цнс | |
| TN2012000559A1 (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| CR20130349A (es) | COMPUESTOS SUSTITUIDOS DE N-(1H- INDAZOL-4-IL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III | |
| MX2012001420A (es) | Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus. | |
| MX2010008198A (es) | Inhibidores de cinasa de pirrolopirazina. | |
| MX2011012353A (es) | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus. | |
| MY160454A (en) | Oxazole substituted indazoles as pi3-kinase inhibitors | |
| PL2250172T3 (pl) | Pirolopirazynowe inhibitory kinazy | |
| TW200942543A (en) | Pyrrolopyrazine kinase inhibitors | |
| PH12012502391A1 (en) | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | |
| WO2010151710A3 (en) | Substituted heterocyclic compounds as kinases inhibitors and method of use thereof | |
| MX2011011735A (es) | Compuestos y metodos para la inhibicion de renina, e indicaciones para ello. | |
| MX2012012614A (es) | Compuestos de 7-(1h-pirazol-4-il)-1, 6-naftiridina como inhibidores de syk. | |
| PT2470546E (pt) | Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor | |
| TN2011000293A1 (en) | Protein kinase inhibitors | |
| WO2011080568A8 (en) | Novel pyrimidine compounds as mtor and pi3k inhibitors | |
| TN2009000389A1 (en) | Pyrido [2,3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer | |
| WO2011079230A3 (en) | Heterocyclic compounds as janus kinase inhibitors | |
| MX2010006331A (es) | Hidantoinas sustituidas como inhibidores de cinasa mek. | |
| UA96745C2 (en) | PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | |
| PH12014501434A1 (en) | Quinoline derivatives as pde10a enzyme inhibitors | |
| EA201171030A1 (ru) | 2-МОРФОЛИНОПИРИДО[3,2-d]ПИРИМИДИНЫ | |
| MX2012006897A (es) | Compuestos heterociclicos como inhibidores de janus cinasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2015 BY COMPUTER PACKAGES INC Effective date: 20141202 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2016 BY COMPUTER PACKAGES INC Effective date: 20151201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2017 BY COMPUTER PACKAGES INC Effective date: 20161201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2018 BY COMPUTER PACKAGES INC Effective date: 20171201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2019 BY COMPUTER PACKAGES INC Effective date: 20181201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2020 BY COMPUTER PACKAGES INC Effective date: 20191203 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2021 BY THOMSON REUTERS Effective date: 20200926 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2022 BY THOMSON REUTERS Effective date: 20211102 |
|
| LAPS | Patent lapsed |